Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + capecitabine + cyclophosphamide + docetaxel + doxorubicin
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen that includes multiple anti-cancer agents with different mechanisms of action. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing tumor angiogenesis. The other components are traditional chemotherapy agents: capecitabine (an antimetabolite), cyclophosphamide (an alkylating agent), docetaxel (a taxane), and doxorubicin (an anthracycline). This combination may be used in clinical trials or specific treatment protocols for various cancers, particularly advanced or metastatic solid tumors.
02
Targets
DNAMicrotubuleTS (Thymidylate synthase)TOP2A (DNA topoisomerase II)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + capecitabine + cyclophosphamide + docetaxel + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + capecitabine + cyclophosphamide + docetaxel + doxorubicin.